Treatment of Diabetic Foot with Autologous Stem Cells: A Meta-Analysis of Randomized Studies

Table 1

Characteristics of the included studies.

	Country	No. of patients		Average age		No. of male		Treatment strategy		Follow-up (months)
		Treatment	Control	Treatment	Control	Treatment	Control	Treatment	Control
Huang 2005	China	14^a	14^b	71.1	70.9	9	9	PBMCs ()+C	Prostaglandin E1+C	3
Lu 2008	China	25	25	66.6	65.5	11	15	BMMSCs (-)+C	C	3
Lu 2011	China	20	41	63	64	—	—	BMMSCs ()+C	Normal saline+C	6
		21		65		—		BMMNCs ()+C
Jain 2011	India	25	23	54	58	17	15	BMMSCs+C	Peripheral blood+C	3
Ozturk 2012	Turkey	20	20	79.9	70.8	16	13	PBMCs (-)+C	C	3
Mohammadzadeh 2013	Iran	7	14	63.5	64.2	—	—	PBMCs (-)+C	PBS+C	12
Han 2010	Korea	26	23	66.5	68.4	15	14	PLA (-)+C	C	2
Kirana 2012	Germany	12	6	68.5	—	9	—	BMMNCs ()+C	C	13
		12		70.9		10		BMTRCs ()+C

PBMC: peripheral blood mononuclear cells; BMMSCs: bone marrow mesenchymal stem cells; BMMNCs: bone marrow mononuclear cells; PLA: Human processed lipoaspirate; BMTRCs: bone marrow-enriched tissue repair cells; C: conventional therapy. ^a14 patients with 23 limbs; ^b14 patients with 24 limbs.